CANSERA INC

Capabilities

Cansera, Inc. applies advanced technology to enhance cancer screening, monitoring, and treatment with the ultimate goal of improving patient outcomes. Our work centers on next-generation rare cell detection technologies powered by modern software architecture, machine learning, and AI-driven analytics. Our flagship platform, CellLogic, identifies and characterizes rare events from fluorescent whole slide imaging (fWSI) of human whole blood and other liquid biopsy samples, enabling highly scalable and clinically relevant insights.